Oxford-based Refeyn secures £56k in latest funding round

Oxford-based Refeyn Ltd has raised £56k in a new funding round, resulting in an estimated post-money valuation of £5.3m. The company specializes in mass photometry, a bioanalytical technology used to measure molecular mass by quantifying light scattering from biomolecules in solution.

Founded in 2018, Refeyn provides instruments for both academic and industrial research, enabling the analysis of single molecules in their native state. The company technology is used in biotherapeutic development and has been cited in more than 1,200 scientific publications. There are currently over 600 global installations of Refeyn hardware.

Financial accounts for the year ended 31 December 2024 show the company generated £18.7m in revenue. During this period, Refeyn recorded a £11.7m loss. The company employs approximately 170 people at its headquarters in Oxford.

The latest £56k investment follows a series of smaller capital raises (allotted in May). In September 2025, the company completed two separate allotments of £57k and £18.6k. Other recent funding includes £10.2k in November 2024 and £12k in July 2024. The current estimated valuation of £5.3m follows a much larger £70m funding round completed in April 2022.

Refeyn technology is designed to provide rapid insights into biomolecular function and structure. Its instruments are utilized in various fields of scientific innovation, including research that has contributed to Nobel Prize winning studies.